866-997-4948(US-Canada Toll Free)

Dengue - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Mar 2014

Category :

Diseases & Conditions

No. of Pages : 164 Pages


This report provides comprehensive information on the therapeutic development for Dengue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dengue and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Dengue
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Dengue and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Dengue products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Dengue pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Dengue
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Dengue pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Dengue Overview 9
Therapeutics Development 10
Pipeline Products for Dengue Overview 10
Pipeline Products for Dengue Comparative Analysis 11
Dengue Therapeutics under Development by Companies 12
Dengue Therapeutics under Investigation by Universities/Institutes 16
Dengue Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Dengue Products under Development by Companies 22
Dengue Products under Investigation by Universities/Institutes 25
Dengue Companies Involved in Therapeutics Development 26
GlaxoSmithKline plc 26
GenVec, Inc. 27
Merck & Co., Inc. 28
Takeda Pharmaceutical Company Limited 29
FIT Biotech Oyj 30
Biological E. Limited 31
Biotron Limited 32
Sarepta Therapeutics, Inc. 33
Medivir AB 34
NanoViricides, Inc. 35
SIGA Technologies, Inc. 36
Panacea Biotec Limited 37
Bharat Biotech International Limited 38
Protein Potential, LLC 39
TechnoVax, Inc. 40
MacroGenics, Inc. 41
PTC Therapeutics, Inc. 42
Chimerix, Inc. 43
Immunotope, Inc. 44
Immunovaccine, Inc. 45
VaxInnate Corporation 46
Janssen Pharmaceuticals, Inc. 47
Cocrystal Discovery, Inc. 48
PaxVax 49
AltraVax Inc. 50
Oneness Biotech Co., Ltd. 51
Arbovax, Inc. 52
Sanofi Pasteur SA 53
Themis Bioscience GmbH 54
Agilvax, Inc. 55
Humabs BioMed SA 56
Codagenix, Inc. 57
Dengue Therapeutics Assessment 58
Assessment by Monotherapy Products 58
Assessment by Combination Products 59
Assessment by Target 60
Assessment by Mechanism of Action 63
Assessment by Route of Administration 66
Assessment by Molecule Type 68
Drug Profiles 71
Dengue Vaccine - Drug Profile 71
DENVax - Drug Profile 73
TetraVax-DV Vaccine-Admixture TV003 - Drug Profile 75
Attenuated Tetravalent Lyophilized Dengue Vaccine - Drug Profile 77
celgosivir hydrochloride - Drug Profile 78
TetraVax-DV Vaccine-Admixture 1 - Drug Profile 79
TetraVax-DV Vaccine-Admixture 2 - Drug Profile 80
TetraVax-DV Vaccine-Admixture TV005 - Drug Profile 81
V-180 - Drug Profile 83
Dengue Vaccine - Drug Profile 84
DENV-1 PIV - Drug Profile 86
ST-148 - Drug Profile 87
DengueCide - Drug Profile 88
TVX-005 - Drug Profile 89
Dengue Vaccine - Drug Profile 90
AVI-6006 - Drug Profile 91
Dengue Vaccine - Drug Profile 92
DV2G460P - Drug Profile 94
squalamine lactate - Drug Profile 96
ST-610 - Drug Profile 97
Dengue Fever Vaccine - Drug Profile 98
Dengue Tetravalent Vaccine - Drug Profile 99
Vaccine For Dengue - Drug Profile 100
Dengue Vaccine - Drug Profile 101
CLEC5A mAb - Drug Profile 102
Dengue Virus Vaccines - Drug Profile 103
Dengue Virus Vacine - Drug Profile 104
Dengue Vaccine - Drug Profile 105
GREDEN/V1-4 - Drug Profile 106
Subunit Vaccine For Dengue - Drug Profile 107
Dengue Vaccine - Drug Profile 108
DEN-2-JE Virus Chimeric Plasmid Vaccine - Drug Profile 109
Chimeric Live-Attenuated Dengue Vaccine - Drug Profile 110
DENV-1/2 prM + E Chimeric Vaccine - Drug Profile 111
Vaccine For Dengue - Drug Profile 112
Small Molecules to Inhibit Furin for Dengue - Drug Profile 113
DV-2-DeltaGVII - Drug Profile 114
DV-2-DeltaLIG - Drug Profile 115
Mult. mAbs/DARTs - Drug Profile 116
Small Molecule for Dengue - Drug Profile 117
Vaccine For Dengue Fever - Drug Profile 118
Small Molecule for Viral Infections - Drug Profile 119
Small Molecule to Inhibit NS3 Protease for Dengue - Drug Profile 120
Viral PMO-X - Drug Profile 121
Small Molecule For Dengue - Drug Profile 122
LCTA-949 - Drug Profile 123
DiTU - Drug Profile 124
BG-323 - Drug Profile 125
Small Moleucles to Activate AMPK for Dengue - Drug Profile 126
Small Molecules to Inhhibit Serine Protease for Viral Infections - Drug Profile 127
Subunit Vaccine for Dengue Fever - Drug Profile 128
Monoclonal Antibody to Inhibit prM and E Proteins for Dengue - Drug Profile 129
PAV-866 - Drug Profile 130
MAb Against Dengue - Drug Profile 131
Vaccine For Dengue Fever - Drug Profile 132
Small Molecule Inhibitors of NS3 Protease for Dengue and West Nile Virus Infections - Drug Profile 133
Protease Inhibitors - Drug Profile 134
ETX-101 - Drug Profile 135
Monoclonal Antibodies for Dengue Fever - Drug Profile 136
Small molecule for Dengue Virus Infections - Drug Profile 137
Vaccine for Dengue Virus Infections - Drug Profile 138
Recombinant Chimeric Recombinant Tetravalent Dengue Vaccine - Drug Profile 139
Recombinant Tetravalent Dengue Vaccine - Drug Profile 140
Dengue Recent Pipeline Updates 141
Dengue Dormant Projects 147
Dengue Discontinued Products 148
Dengue Product Development Milestones 149
Featured News & Press Releases 149

Appendix 159
Methodology 159
Coverage 159
Secondary Research 159
Primary Research 159
Expert Panel Validation 159
Contact Us 160
Disclaimer 160

List of Table


Number of Products under Development for Dengue, H1 2014 14
Number of Products under Development for Dengue Comparative Analysis, H1 2014 15
Number of Products under Development by Companies, H1 2014 17
Number of Products under Development by Companies, H1 2014 (Contd..1) 18
Number of Products under Development by Companies, H1 2014 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2014 21
Comparative Analysis by Late Stage Development, H1 2014 22
Comparative Analysis by Clinical Stage Development, H1 2014 23
Comparative Analysis by Early Stage Development, H1 2014 24
Comparative Analysis by Unknown Stage Development, H1 2014 25
Products under Development by Companies, H1 2014 26
Products under Development by Companies, H1 2014 (Contd..1) 27
Products under Development by Companies, H1 2014 (Contd..2) 28
Products under Investigation by Universities/Institutes, H1 2014 29
Dengue Pipeline by GlaxoSmithKline plc, H1 2014 30
Dengue Pipeline by GenVec, Inc., H1 2014 31
Dengue Pipeline by Merck & Co., Inc., H1 2014 32
Dengue Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 33
Dengue Pipeline by FIT Biotech Oyj, H1 2014 34
Dengue Pipeline by Biological E. Limited, H1 2014 35
Dengue Pipeline by Biotron Limited, H1 2014 36
Dengue Pipeline by Sarepta Therapeutics, Inc., H1 2014 37
Dengue Pipeline by Medivir AB, H1 2014 38
Dengue Pipeline by NanoViricides, Inc., H1 2014 39
Dengue Pipeline by SIGA Technologies, Inc., H1 2014 40
Dengue Pipeline by Panacea Biotec Limited, H1 2014 41
Dengue Pipeline by Bharat Biotech International Limited, H1 2014 42
Dengue Pipeline by Protein Potential, LLC, H1 2014 43
Dengue Pipeline by TechnoVax, Inc., H1 2014 44
Dengue Pipeline by MacroGenics, Inc., H1 2014 45
Dengue Pipeline by PTC Therapeutics, Inc., H1 2014 46
Dengue Pipeline by Chimerix, Inc., H1 2014 47
Dengue Pipeline by Immunotope, Inc., H1 2014 48
Dengue Pipeline by Immunovaccine, Inc., H1 2014 49
Dengue Pipeline by VaxInnate Corporation, H1 2014 50
Dengue Pipeline by Janssen Pharmaceuticals, Inc., H1 2014 51
Dengue Pipeline by Cocrystal Discovery, Inc., H1 2014 52
Dengue Pipeline by PaxVax, H1 2014 53
Dengue Pipeline by AltraVax Inc., H1 2014 54
Dengue Pipeline by Oneness Biotech Co., Ltd., H1 2014 55
Dengue Pipeline by Arbovax, Inc., H1 2014 56
Dengue Pipeline by Sanofi Pasteur SA, H1 2014 57
Dengue Pipeline by Themis Bioscience GmbH, H1 2014 58
Dengue Pipeline by Agilvax, Inc., H1 2014 59
Dengue Pipeline by Humabs BioMed SA, H1 2014 60
Dengue Pipeline by Codagenix, Inc., H1 2014 61
Assessment by Monotherapy Products, H1 2014 62
Assessment by Combination Products, H1 2014 63
Number of Products by Stage and Target, H1 2014 66
Number of Products by Stage and Mechanism of Action, H1 2014 69
Number of Products by Stage and Route of Administration, H1 2014 71
Number of Products by Stage and Molecule Type, H1 2014 74
Dengue Therapeutics Recent Pipeline Updates, H1 2014 145
Dengue Dormant Projects, H1 2014 151
Dengue Discontinued Products, H1 2014 152

List of Chart


Number of Products under Development for Dengue, H1 2014 14
Number of Products under Development for Dengue Comparative Analysis, H1 2014 15
Number of Products under Development by Companies, H1 2014 16
Number of Products under Investigation by Universities/Institutes, H1 2014 20
Comparative Analysis by Clinical Stage Development, H1 2014 23
Comparative Analysis by Early Stage Products, H1 2014 24
Comparative Analysis by Unknown Stage Development, H1 2014 25
Assessment by Monotherapy Products, H1 2014 62
Number of Products by Top 10 Target, H1 2014 64
Number of Products by Stage and Top 10 Target, H1 2014 65
Number of Products by Top 10 Mechanism of Action, H1 2014 67
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 68
Number of Products by Top 10 Route of Administration, H1 2014 70
Number of Products by Stage and Top 10 Route of Administration, H1 2014 71
Number of Products by Top 10 Molecule Type, H1 2014 72
Number of Products by Stage and Top 10 Molecule Type, H1 2014 73

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *